ADCs are targeted cancer medicines that deliver cytotoxic chemotherapy
to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells.
Most patients received cytotoxic chemotherapy
, and 25 (63%) had estrogen receptor-positive cancer.
Embraca is a global, open-label, randomised, parallel and two-arm study of talazoparib against protocol-specific physician's choice of standard single-agent chemotherapy in gBRCA+ patients who may have received up to three prior cytotoxic chemotherapy
regimens for locally advanced and/or metastatic breast cancer.
MYLOTARG was originally approved in 2000 at a higher dose under the FDA's accelerated approval program for use as a single agent in patients with CD33-positive AML who had experienced their first relapse and were 60 years or older and who were not considered candidates for other cytotoxic chemotherapy
Antibody drug conjugates (ADCs) are a type of targeted cancer medicine that deliver cytotoxic chemotherapy
(payload) directly to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells.
Ever since the advent of cytotoxic chemotherapy
, quantum leaps can be counted on fingers.
These include cytotoxic chemotherapy
, hormonal and biologic therapies, such as monoclonal antibodies, targeted small molecules such as kinase inhibitors, immunotherapies such as checkpoint inhibitors, antibody-drug conjugates and radiolabelled (tracing) agents.
is a form of cell-cycle dependent therapy that kills cancer cells by interfering with different phases of the cell cycle.
This methodology differs from the more observed approach used in orthodox cytotoxic chemotherapy
, which has continued to be the backbone of cancer treatment over past several years.
Though there are anecdotal reports of responses in NSCLC with these genotypes, no targeted therapy has been found that consistently induces the dramatic responses we hope for, and cytotoxic chemotherapy
remains the standard treatment.
T-DM1 is a type of medicine called an antibody-drug conjugate and it connects two anti-cancer properties: the HER2 inhibition of trastuzumab and the cytotoxic chemotherapy
3 million residents of nursing homes across the country to characterize the use of medications that have been deemed "never appropriate" in this patient population: cholinesterase inhibitors, memantine, antiplatelet agents other than aspirin, lipid-lowering drugs, sex hormones, hormone antagonists, leukotriene inhibitors, cytotoxic chemotherapy
, and immunomodulators.